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Biol Blood Marrow Transplant 18:1776-1784, 2012 1777Late Effects after HCT in SAA1-year HCT survivors with SAA. Of the HCTrecipients, 1176 (68.5%) and 542 (31.5%) patients underwent
a matched sibling donor (MSD) or unrelated donor (URD) HCT, respectively. The median age at the time of
HCTwas 20 years. The median interval from diagnosis to transplantation was 3 months for MSDHCTand 14
months for URD HCT. The median follow-up was 70 months and 67 months for MSD and URD HCT sur-
vivors, respectively. Overall survival at 1 year, 2 years, and 5 years for the entire cohort was 76% (95% con-
fidence interval [CI]: 74-78), 73% (95% CI: 71-75), and 70% (95% CI: 68-72). Among 1-year survivors of MSD
HCT, 6% had 1 late effect and 1% had multiple late effects. For 1-year survivors of URD HCT, 13% had 1 late
effect and 2% had multiple late effects. Among survivors of MSD HCT, the cumulative incidence estimates of
developing late effects were all\3% and did not increase over time. In contrast, for recipients of URD HCT,
the cumulative incidence of developing several late effects exceeded 3% by 5 years: gonadal dysfunction
10.5% (95% CI: 7.3-14.3), growth disturbance 7.2% (95% CI: 4.4-10.7), avascular necrosis 6.3% (95% CI:
3.6-9.7), hypothyroidism 5.5% (95% CI: 2.8-9.0), and cataracts 5.1% (95% CI: 2.9-8.0). Our results indicated
that all patients undergoing HCT for SAA remain at risk for late effects, must be counseled about, and should
be monitored for late effects for the remainder of their lives.
Biol Blood Marrow Transplant 18: 1776-1784 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Hematopoietic cell transplant, Allogeneic, Survivorship, Severe aplastic anemia, Late effectsINTRODUCTION
Hematopoietic cell transplant (HCT) has been
used successfully to treat acquired severe aplastic
anemia (SAA) for several decades [1-5]. In the last 2
decades, a significant improvement in outcomes
has been reported in patients with SAA undergoing
matched sibling donor (MSD) or unrelated donor
(URD) HCT [3-5]. As a result of improvements
in HCT for acquired SAA, which include decreased
risk of graft failure and conditioning-related toxicity
and improvements in donor selection and supportive
care, there is a growing population of HCT survivors
with acquired SAA. Despite the documentation of se-
vere and life-threatening chronic health conditions or
so-called ‘‘late effects’’ in HCT survivors of malignant
disorders [6,7], the impact of HCT in nonmalignant
disorders has been the subject of limited evaluation.
The overlap between HCT-related toxicities and
toxicities associated with pre-HCT treatment of ac-
quired SAA suggests a need to better characterize late
effects after HCT in patients with acquired SAA.
A few small studies describe the variable risk of
malignant and nonmalignant late effects in HCT
survivors with acquired SAA [8-16]. Despite the
toxicity of pre-HCT SAA therapy, conditioning-
related toxicity, and HCT-related complications, the
long-term impact of HCT on this population has not
been adequately characterized. Table 1 describes prior
work that characterizes late effects in acquired SAA.
Limitations include single-institution studies with
small numbers of HCT survivors with acquired SAA
represented [8-16]. Other studies describe the burden
of select late effects in HCT survivor cohorts of
limited representation with respect to age at the time
of HCT, donor type, and conditioning exposures.
The purpose of our study was to address this gap in
the past literature by describing the cumulative
incidence of late effects (neurological, cardiovascular,gastrointestinal, genitourinary, musculoskeletal, sen-
sory, endocrine, hematologic, and malignancy) in
a large and representative cohort of HCT survivors
with acquired SAA using data reported to the Center
for International Blood and Marrow Transplant
Research (CIBMTR) [17].MATERIALS AND METHODS
Data Sources
The CIBMTR is a research affiliation of the In-
ternational Bone Marrow Transplant Registry, Autol-
ogous Blood and Marrow Transplant Registry, and
the National Marrow Donor Program established in
2004. It comprises a voluntary working group of
more than 450 transplantation centers worldwide
that contribute detailed data on consecutive alloge-
neic and autologous HCT procedures to a statistical
center at the Medical College of Wisconsin in Mil-
waukee and the National Marrow Donor Program
Coordinating Center in Minneapolis, Minnesota.
Participating centers are required to report all trans-
plantations consecutively; compliance is monitored
by on-site audits. Patients are followed longitudinally.
Computerized checks for discrepancies, physicians’
review of submitted data, and on-site audits of partici-
pating centers ensure data quality. Observational
studies conducted by the CIBMTR are performed
in compliance with all applicable federal regulations
pertaining to the protection of human research partic-
ipants. Protected health information used in the per-
formance of such research is collected and maintained
in CIBMTR’s capacity as a Public Health Authority
under the Health Insurance Portability and Account-
ability Act Privacy Rule.
The CIBMTR collects data at 2 levels: transplant
essential data (TED) and comprehensive report form
(CRF) data. TED data include disease type, age, sex,
Table 1. Summary of Studies Reporting Late Effects after HCT for Severe Aplastic Anemia
Study Patient Demographics
Donor
Characteristics
Conditioning
Regimen(s)
Follow-up, Survival,
and cGVHD Late Effects
Socie et al., 1991 N 5 107
1980-1989
Median age HCT
16 years (6-24)
MSD BM Cy + TAI Mean 64 months
OS – not given
cGVHD 45.5%
CI at 8 years
Cancer 22% (SE 11%)
Socie et al., 1993 N 5 748
1971-1991
Mean age Dx
18 years (1 months-59 years)
MSD BM (90%)
SYN (2%)
Alternative (8%)
Cy (54%)
Cy + TLI/TAI (35%)
Cy + TBI (8%)
None (3%)
Mean 47 months
OS – not given
cGVHD – not given
CI at 10 years
Cancer 3.1%
Deeg et al., 1996 N 5 621
1970-1993
Median age HCT
19 years (1.8-67 years)
MSD BM (89%)
MMRD/MUD (11%)
Cy (66%)
Cy + ATG ± PC (11%)
Cy + TBI/TAI (40%)
Mean 47 months
OS – not given
cGVHD 30.8%
CI at 20 years
Cancer 14% (4-24)
Deeg et al., 1998 N 5 212
1970-1993
Median age HCT
18 years (1-42)
MSD BM (88%)
MMRD BM (8%)
MUD BM (2%)
SYN BM (1%)
Cy (44%)
Cy + Buffy (31%)
Cy + ATG (18%)
Cy + TBI (7%)
None (<1%)
Median 12 years
20-year OS 69%-89%
cGVHD 41%
Osteonecrosis 18%
Cancer 12%
Depression 19%
Female pregnant 47%
Male father 50%
Eapen et al., 2000 N 5 37 patients/146 controls
1975-1996
Median age HCT
7 years (1-21)
MSD BM (86%)
MMRD (5%)
MUD (8%)
Cy + TLI (78%)
Cy + TBI (13%)
Other (8%)
Median 17 years
5-year OS 67%
cGVHD 21.6%
Cataract OR 16
Hypothyroid OR 14.25
Estrogen OR 5.85
Ades et al., 2004 N 5 133
1978-2001
Age at HCT
<15 years (38%)
15-30 years (44%)
>30 years (18%)
MSD BM Cy + ATG (25%)
Cy + TAI (75%)
Median 13.6 years
10-year OS 64.5%
cGVHD 60%
CI at 15 years
Osteonecrosis 19.6%
Cancer 10.9%
Hypothyroid (1 patient)
Cataracts (2 patients)
Depression (12 patients)
Sanders et al., 2011 N 5 137
1971-2009
Median age at HCT
11.1 years (0.8-17.9)
RD (86%)
MUD (12%)
SYN (2%)
BM (98%)
CB (2%)
Cy ± ATG (77%)
PC + Cy + ATG (4%)
Cy + TBI (18%)
None (1%)
Median 21.8 years
30-year OS 82%
cGVHD 26%
BMD abnormal 26%
Cancer 13%
Thyroid abnormal 22%
Growth abnormal 0%
Gonadal abnormal 22%/17%
(pre-/post-puberty girl)
38%/0% (pre-/post-puberty boy)
Female pregnant 42%
Male father 37%
Konopacki et al., 2011 N 5 61
1991-2010
Median age at HCT
21 years (4-43 years)
MSD BM (97%)
MSD BM/PB (3%)
Cy + ATG Median 73 months
6-year OS 87.5%
cGVHD 32%
CI at 72 months
Osteonecrosis 21%
Endo abnormal 19%
Cardio abnormal 2%
Cancer 2% (0-11)
Female pregnant 5%
Male father 7%
HCT indicates hematopoietic cell transplant; cGVHD, chronic graft-versus-host disease; MSD, matched sibling donor; BM, bone marrow; Cy, cytoxan;
TAI, thoracoabdominal irradiation; OS, overall survival; CI, cumulative incidence; Dx, diagnosis; SYN, syngeneic; TLI, total lymphoid irradiation; TBI, total
body irradiation; MMRD, mismatched related donor; MUD, matched unrelated donor; ATG, antithymocyte globulin; PC, procarbazine; OR, odds ratio;
RD, related donor; CB, cord blood; BMD, bone mineral density; PB, peripheral blood.
1778 Biol Blood Marrow Transplant 18:1776-1784, 2012D. Buchbinder et al.pretransplantation disease stage and chemotherapy re-
sponsiveness, date of diagnosis, graft type (bone
marrow-derived and/or blood-derived stem cells),
conditioning regimen, posttransplantation disease
progression and survival, development of a new malig-
nancy, and cause of death. All CIBMTR teams con-
tribute TED data. More detailed disease and
pretransplantation and posttransplantation clinical in-
formation are collected on a subset of registered
patients selected for CRF data by a weighted random-
ization scheme. TED- and CRF-level data are col-
lected pretransplantation, 100 days, 6 months
posttransplantation, and annually thereafter or until
death. Data for these analyses were retrieved from
CIBMTR (TED and CRF) report forms.Study Population
The study population included patients who un-
derwent allogeneic HCT between 1995 and 2006 for
acquired SAA and were reported to the CIBMTR
using CRF data. Patients with a diagnosis of myelodys-
plastic syndrome or an inherited bone marrow failure
syndrome were excluded from the study population.
Recipients of MSD or URD HCT were included in
these analyses. Overall, 2653 patients met our study el-
igibility criteria. HCT procedures involving identical
twin donors or other related donors were excluded
from these analyses (N 5 110). Patients reported
from transplant centers with a follow-up completeness
index of \80% at 5 years were also excluded from
these analyses (N 5 825 patients from 90 centers)
Biol Blood Marrow Transplant 18:1776-1784, 2012 1779Late Effects after HCT in SAA[18]. Our final study population consisted of 1718 pa-
tients from 186 centers (1176 MSD and 542 URD
HCT recipients).
Data Collection on Late Effects
The primary outcomes chosen for analysis were late
effects occurring post-HCT. Transplant centers re-
ported late effects as part of follow-up CRFs that in-
quired whether an HCT recipient had developed any
clinically significant organ impairment or disorder since
the date of the last report. Specific questions focused on
the following late effects: neurological (stroke/seizures),
cardiovascular (myocardial infarction), gastrointestinal/
hepatic (cirrhosis), genitourinary (gonadal dysfunction/
infertility requiring hormone replacement, renal failure
severe enough to warrant dialysis), musculoskeletal
(avascular necrosis), special sensory (cataracts), and en-
docrine (growth hormone deficiency/growth distur-
bance, hypothyroidism) impairment. Responses to
each item were dichotomous (yes/no) and followed by
a question requesting the date of onset for each individ-
ual organ impairment or disorder. Other late effects
were reported using an ‘‘other-specify’’ field that was
also checked for the late effects of interest. Pregnancy
datawas collected from2002 to 2007 onHCT survivors
who underwent HCT before 2007. Transplant centers
were queried regarding whether the survivor or the sur-
vivor’s partner became pregnant or had successfully fa-
thered a child. Onset dates of late effects were
collected on report forms beginning in 2007. Before
2007, onset dateswere collected only for newonset solid
tumors. Thus, for cases before 2007, the onset date for
late effects of nonmalignant origin was imputed as the
median time point between successive report forms
that were submitted before and after onset of the speci-
fied late effect. The questionnaires used by the
CIBMTR can be viewed at www.cibmtr.org [17].
Statistical Analysis
Descriptive statistics were calculated for socio-
demographic, SAA treatment-related variables, and
HCT-related variables. Classification of HLA-matching
was completed using 3 groups including well-
matched cases, partially matched cases, and mis-
matched cases, as previously described [19]. We
determined the prevalence of late effects among
HCT survivors. For the prevalence estimates, 3 out-
comes were assessed including no late effects, the pres-
ence of 1 late effect, and multiple late effects ($2).
Cumulative incidence rates of individual late effects
are reported herein for 1-year condition-free survivors
(ie, survivors without a previous diagnosis of the spec-
ified late effect). The cumulative incidence of late ef-
fects was calculated with death not related to the late
effect treated as a competing event. Patients who did
not develop the conditions were censored at the lastresearch-level follow-up. Cumulative incidence
estimates are provided herein with 95% confidence in-
tervals (CIs). Due to the limited number of events in
our sample, we were unable to complete multivariable
analyses. This report presents descriptive analyses
only. SAS, version 9.2 (SAS Institute, Cary, NC) was
used for all analyses.RESULTS
Patient, Disease, and Transplant Characteristics
Patient, disease, and transplant characteristics of
the study population are described in Table 2. The
most common etiology of SAA for recipients in both
MSD and URD groups was idiopathic, followed by
viral and toxin or drug-related. The proportion of
HCT procedures for SAA by transplant type shifted
over time from a majority being MSD procedures
(61%) to the majority being URD procedures (64%).
The majority of MSD HCT procedures (72%)
occurred outside of the United States and Canada;
however, the majority of URD HCT procedures
(73%) occurred within the United States and Canada.
Of the HCT recipients, 1176 patients (68.5%) with
a median age at HCT of 20 years (range:\1-65 years)
received an MSD, and 542 patients (31.5%) with a me-
dian age at HCT of 20 years (range:\1-67 years) re-
ceived a URD. The median interval from diagnosis to
transplantation was 3 months (range:\1-348 months)
for MSD HCT and 14 months (range: 1-318 months)
for URD HCT. Bone marrow was the predominant
graft source for both MSD and URD (88% and 77%,
respectively). Approximately one-third of the URD
HCTprocedures used a well-matched donor. Although
total body irradiation (TBI) was used in 68% of URD
HCT cases at a median dose of 600 cGy (range: 200-
1530 cGy), it was used in only 4% of MSD cases with
a median dose of 800 cGy (range: 200-1410 cGy). Bu-
sulfan was used in 22% of MSD HCT cases and 8%
of URD HCT cases with a median dose of 12 mg/kg
(range:\1-51 mg/kg) and 13 mg/kg (range: 2-40 mg/
kg), respectively. Busulfan and fludarabine were used
for conditioning in 50% of MSD HCT cases, and
cyclophosphamide in combination with TBI was used
as a conditioning regimen in 68% of URDHCT cases.
Acute graft-versus-host disease (aGVHD) prophylaxis
consisted of cyclosporine and methotrexate in 81%
and 46% of MSD and URD cases, respectively. Antith-
ymocyte globulin (ATG) and/or alemtuzumab were
used in 59% of the MSD HCT procedures and 72%
of the URD HCT procedures.Survival and GVHD
The median follow-up was 70 months (range:
1-160 months) and 67 months (range: 3-182 months)
Table 2. Patient, Disease, and Transplantation Characteris-
tics of the Study Population (N 5 1718)
Characteristic
HLA-matched
sibling donor Unrelated donor
Frequency (%) Frequency (%)
Number of patients 1176 (68) 542 (32)
Median age at transplant
in years (range)
20 (<1-65) 20 (<1-67)
Age at transplant
0-9 years 187 (16) 111 (20)
10-19 years 388 (33) 170 (31)
20-29 years 305 (26) 127 (23)
30-39 years 175 (15) 73 (13)
40-49 years 91 (8) 33 (6)
50-59 years 27 (2) 20 (4)
$60 years 3 (<1) 8 (1)
Recipient sex
Female 518 (44) 236 (44)
Male 658 (56) 306 (56)
Etiology of aplastic anemia
Idiopathic 979 (83) 490 (90)
Viral hepatitis 61 (5) 22 (4)
Toxin or other drug 47 (4) 12 (2)
Other* 89 (8) 18 (3)
Transplant team region
United States/Canada 331 (28) 396 (73)
Europe 130 (11) 56 (10)
Other† 751 (61) 90 (17)
Interval from diagnosis to
transplant
<6 months 793 (67) 107 (20)
6-12 months 127 (11) 126 (23)
>12 months 255 (22) 307 (57)
Year of transplant
1995-2000 713 (61) 194 (36)
2001-2006 463 (39) 348 (64)
Graft source
BM 1031 (88) 416 (77)
PB 140 (12) 81 (15)
CB 5 (<1) 45 (8)
Number of transplant
1 1068 (91) 505 (93)
$2 108 (9) 37 (7)
Degree of HLA match
HLA-matched siblings 1176 0
Well matched 0 167 (31)
Partially matched 0 130 (24)
Mismatched 0 83 (15)
Unknown 0 162 (30)
Conditioning regimen
TBI + Cy 38 (3) 366 (68)
Busulfan + Cy 221 (19) 28 (5)
Cy + fludarabine 89 (8) 40 (7)
Busulfan + fludarabine 29 (2) 14 (3)
Cy + ATG 588 (50) 59 (11)
Cy + other 186 (16) 15 (3)
Other/unknown 25 (2) 20 (4)
Irradiation as part of conditioning
None 1095 (94) 119 (22)
TBI 45 (4) 372 (69)
TLI/TAI only 30 (3) 51 (9)
Total TBI dose
None 1125 (96) 170 (31)
<400 cGy 18 (2) 135 (25)
>400 cGy 27 (2) 236 (44)
GVHD prophylaxis
Ex vivo T cell depletion ±
immunosuppression
13 (1) 36 (7)
FK506 + MMF ± other (not MTX) 14 (2) 45 (8)
FK506 + MTX + other 45 (4) 122 (23)
CSA + MMF ± other (not MTX) 100 (8) 76 (14)
(Continued )
Table 2. (Continued )
Characteristic
HLA-matched
sibling donor Unrelated donor
Frequency (%) Frequency (%)
CSA + MTX + other 949 (81) 249 (46)
Other 49 (4) 10 (2)
Unknown 6 (1) 4 (1)
Use of ATG/Campath
No 486 (41) 154 (28)
Yes 690 (59) 388 (72)
BM indicates bone marrow; PB, peripheral blood; CB, cord blood; TBI,
total body irradiation; Cy, cytoxan; ATG, antithymocyte globulin; TLI,
total lymphoid irradiation; TAI, thoracoabdominal irradiation; GVHD,
graft-versus-host disease; MMF, mycophenolate mofetil; MTX, metho-
trexate; CSA, cyclosporine.
*Other etiologies included paroxysmal nocturnal hemoglobinuria
(N 5 71), acquired amegakaryocytosis (N 5 7), acquired pure red
cell aplasia (N 5 6), and other acquired cytopenias (N 5 23).
†Other regions represented include Argentina (N 5 19), Australia
(N 5 30), Brazil (N 5 310), Japan (N 5 12), Korea (N 5 269), New
Zealand (N 5 14), Saudi Arabia (N 5 123), Taiwan (N 5 5), Mexico
(N 5 2), Hong Kong (N 5 13), and Uruguay (N 5 8).
1780 Biol Blood Marrow Transplant 18:1776-1784, 2012D. Buchbinder et al.forMSD andURD cases, respectively. Overall survival
at 1 year, 2 years, and 5 years for the entire cohort was
76% (95%CI: 74-78), 73% (95%CI: 71-75), and 70%
(95% CI: 68-72), respectively. Causes of death among
the MSDHCT group included: 87 (32%) deaths from
infection, 60 (22%) deaths from organ failure, 40
(14%) deaths from graft rejection, 33 (12%) deaths
from hemorrhage, and 27 (10%) deaths from
GVHD. Nine patients (3%) developed malignancies
resulting in death, and 6 patients (2%) developed inter-
stitial pneumonitis also resulting in death. For the
URDHCT group, 82 patients (33%) died from infec-
tion, 58 patients (23%) died from organ failure, 21
patients (8%) died from graft rejection, 24 patients
(10%) died from hemorrhage, and 43 patients (17%)
died from GVHD. Eight patients (3%) developed
malignancies resulting in death, and 8 patients (3%)
developed interstitial pneumonitis also resulting in
death. Other transplantation-related deaths were
reported for the entire cohort including 14 (5%)
among the MSD HCT group and 7 (3%) among the
URD HCT group. Other causes of death included
9 vascular complications resulting in death and 6 acci-
dental deaths.
The overall cumulative incidence of aGVHD at
day 1100 was 17% (95% CI: 15-19) and 44% (95%
CI: 40-49) among the MSD and URD recipients, re-
spectively. For chronic GVHD (cGVHD), the cumu-
lative incidence at 1 year, 2 years, and 5 years for MSD
was 16% (95% CI: 14-19), 20% (95% CI: 18-22), and
22% (95% CI: 20-24), respectively, whereas, for the
same time periods, the cumulative incidence of
cGVHD among URD recipients was higher at 33%
(95% CI: 29-37), 37% (95% CI: 32-41), and 37%
(95% CI: 33-42), respectively.
Table 3. Prevalence of Late Effects among 1718 Survivors >1
Year Post-HCT for Acquired SAA between 1995 and 2006
Reported to the CIBMTR According to Donor
Related Donor Unrelated Donor
N (%) N (%)
1-year survivors
No late effects 898 (93) 285 (85)
One late effect 61 (6) 44 (13)
Multiple late effects 5 (1) 6 (2)
2-year survivors
No late effects 822 (90) 245 (80)
One late effect 81 (9) 54 (18)
Multiple late effects 11 (1) 9 (3)
5-year survivors
No late effects 586 (87) 116 (61)
One late effect 77 (11) 48 (25)
Multiple late effects 12 (2) 27 (14)
SAA indicates severe aplastic anemia; CIBMTR, Center for International
Blood and Marrow Transplant Research.
Table 4. Interval-Specific Cumulative Incidence Rates of
Select Late Effects among 1-Year Condition-Free Survivors
Post-HCT for Acquired SAAbetween 1995 and 2006 Reported
to the CIBMTR According to Donor Type
Related Donor
Unrelated
Donor
No. at
Risk % (95% CI)
No. at
Risk % (95% CI)
Late effect
Stroke/seizures
Over next 2 years 707 1.7 (0.9-2.7) 283 1.3 (0.3-2.8)
Over next 5 years 416 1.8 (1.0-2.9) 118 2.8 (1.2-5.1)
Myocardial infarction
Over next 2 years 736 0 293 0
Over next 5 years 435 0.1 (0.0-0.5) 127 0
Cirrhosis
Over next 2 years 737 0 290 0.3 (0.0-1.2)
Over next 5 years 436 0 127 0.3 (0.0-1.2)
Gonadal dysfunction/infertility
Over next 2 years 709 2.6 (1.6-3.8) 273 6.2 (3.8-9.1)
Over next 5 years 419 3.0 (2.0-4.3) 108 10.5 (7.3-14.3)
Renal failure
Over next 2 years 715 1.1 (0.5-1.9) 287 1.9 (0.7-3.6)
Over next 5 years 425 1.4 (0.7-2.3) 127 2.4 (0.9-4.5)
Avascular necrosis
Over next 2 years 724 1.4 (0.7-2.3) 276 3.2 (1.5-5.4)
Over next 5 years 426 1.8 (1.0-2.8) 117 6.3 (3.6-9.7)
Cataracts
Over next 2 years 734 0.6 (0.2-1.2) 284 2.2 (0.9-4.1)
Over next 5 years 433 1.1 (0.5-1.9) 118 5.1 (2.9-8.0)
Growth disturbance
Over next 2 years 735 0.2 (0.0-0.7) 286 1.9 (0.7-3.6)
Over next 5 years 433 0.5 (0.1-1.2) 113 7.2 (4.4-10.7)
Hypothyroidism
Over next 2 years 731 0.7 (0.3-1.4) 286 0.6 (0.1-1.8)
Over next 5 years 432 1.2 (0.5-2.1) 119 5.5 (2.8-9.0)
Solid tumors
Over next 2 years 852 0.2 (0.0-0.6) 291 0.6 (0.1-1.8)
Over next 5 years 549 0.3 (0.1-0.8) 126 1.6 (0.5-3.3)
Lymphoma
Over next 2 years 851 0.1 (0.0-0.4) 280 0.6 (0.1-1.8)
Over next 5 years 550 0.1 (0.0-0.4) 124 0.6 (0.1-1.8)
HCT indicates hematopoietic cell transplant; SAA, severe aplastic ane-
mia; CIBMTR, Center for International Blood and Marrow Transplant
Research; CI, confidence interval.
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Prevalence and cumulative incidence
Table 3 provides the prevalence of the total
number of late effects among HCT survivors. Among
1-year survivors of MSD HCT, 6% had 1 late effect
and 1% had multiple late effects. Among 5-year
MSD HCT survivors, these percentages increased to
11% and 2%, respectively. For URD HCT survivors,
13% had 1 late effect and 2% had multiple late effects.
Among 5-year URD HCT survivors, these percent-
ages continued to increase with 25% demonstrating 1
late effect and 14%demonstratingmultiple late effects.
Table 4 demonstrates the cumulative incidence of
late effects among 1-year survivors after MSD and
URD HCT for acquired SAA. Among MSD HCT
survivors, the cumulative incidence of late effects
was #3%. Gonadal dysfunction represented the most
common late effect. Among 1-year MSD HCT survi-
vorswith no gonadal dysfunction (condition-free survi-
vors), the cumulative incidence of developing gonadal
dysfunction over the next 2 years was 2.6% (95% CI:
1.6-3.8) and over the next 5 years was 3.0% (95% CI:
2.0-4.3). In general, the cumulative incidence of late
effects in the MSD group did not increase over the
specified time intervals.
A total of 32 pregnancies were reported, including
22 female HCT recipients (69%) and 10 partners of
male HCT survivors (32%). Nearly all (32 cases;
97%) of the reported pregnancies were reported in
the setting of MSD HCT. Conditioning regimens
amongHCT survivors reporting pregnancies included
cyclophosphamide and ATG (18 cases; 56%), cyclo-
phosphamide (9 cases; 28%), and busulfan in combina-
tion with cyclophosphamide (3 cases; 9%). One
pregnancy occurred after exposure to cyclophospha-
mide in combination with ATG and total lymphoid
irradiation, and 1 pregnancy occurred after exposureto cyclophosphamide in combination with fludarabine
and alemtuzumab.Demographic Factors
No differences in the proportion of affected survi-
vors were noted among pediatric (0-18 years) MSD
HCT survivors when compared to adult (.18 years)
MSD HCT survivors across all late effects under eval-
uation. ForURDHCT survivors, a greater proportion
of adult HCT survivors (8%) developed avascular ne-
crosis compared to pediatric HCT survivors (3%),
whereas a greater proportion of growth disturbance
was noted among pediatric HCT survivors (14%)
compared to none of the adult HCT survivors.
With respect to sex, no differences in the propor-
tion of affected survivors were noted among male
MSD HCT survivors when compared with female
MSD HCT survivors across all late effects under
1782 Biol Blood Marrow Transplant 18:1776-1784, 2012D. Buchbinder et al.evaluation, with few exceptions. Female MSD HCT
survivors demonstrated a greater proportion (6%) of
gonadal dysfunction when compared with male MSD
HCT survivors (1%). For URD HCT survivors,
a greater proportion of female HCT survivors (15%)
developed gonadal dysfunction compared with male
HCT survivors (6%), whereas a greater proportion of
growthdisturbancewas noted amongmaleHCTsurvi-
vors (8%) compared with female HCT survivors (5%).
Donor Type
Among URDHCT survivors, the cumulative inci-
dence estimated for late effects in general was higher
than the estimates among MSD survivors. For exam-
ple, the cumulative incidence of developing gonadal
dysfunction among 1-year condition-free survivors
was 6.2% (95% CI: 3.8-9.1) over the next 2 years
and 10.5% (95% CI: 7.3-14.3) over the next 5 years.
The estimates of cumulative incidence for other late
effects developing over the next 5 years included in
condition-free 1-year survivors was (in decreasing or-
der of incidence): growth disturbance 7.2% (95% CI:
4.4-10.7), avascular necrosis 6.3% (95% CI: 3.6-9.7),
hypothyroidism 5.5% (95% CI: 2.8-9.0), and cataracts
5.1% (95% CI: 2.9-8.0). All other late effects demon-
strated cumulative incidence estimates\3%. In con-
trast to the MSD group, the cumulative incidence of
late effects in the URD group increased over the spec-
ified time intervals.
The cumulative incidence of developing a solid
tumor over the next 2 years among survivors of MSD
and URD HCT was similar at 0.2% (95% CI: 0.0-
0.6) and 0.6% (95% CI: 0.1-1.8), respectively. For
URD HCT survivors, this estimate increased to
1.6% (95% CI: 0.5-3.3) over the next 5 years. Sites
of secondary solid tumors in the MSDHCT group in-
cluded colon (N5 1), lung (N5 1), soft tissue (N5 1),
thyroid (N5 1), and uterus (N5 1). One case was un-
known in the MSD HCT group. For the URD HCT
group, the sites of secondary solid tumors included
esophagus (N 5 1), Kaposi sarcoma (N 5 1), mela-
noma (N 5 1), prostate (N 5 1), soft tissue (N 5 1),
thyroid (N 5 1), and vagina (N 5 1).
Conditioning Exposures and cGVHD
Among MSD and URD HCT survivors, a greater
proportion of late effects occurred in those exposed to
TBI. For MSD HCT survivors, gonadal dysfunction
occurred in 11% of survivors exposed to TBI com-
pared with 3%without TBI exposure. Similar findings
were noted for URDHCT survivors (12% versus 5%).
Cataracts occurred in 11% of MSD HCT survivors
with TBI exposure and 1% without TBI exposure. A
similar pattern was noted for cataracts in URD HCT
survivors (7% versus 1%). The proportion of MSD
HCT survivors with hypothyroidism was 5% in those
with TBI exposure and 1% in those without. Similarfindings were noted for URD HCT survivors. Hypo-
thyroidism was noted in 6% of survivors exposed to
TBI versus 1% of those not exposed to TBI. For solid
tumors, 2% of URD HCT survivors exposed to TBI
developed a malignancy versus 1% not exposed.
AmongURDHCT survivors, a greater proportion
of late effects was noted in those with cGVHD. For
URD HCT survivors, gonadal dysfunction occurred
in 13% of survivors with cGVHD compared with
8% without cGVHD. Cataracts occurred in 8% of
URD HCT survivors with cGVHD and 4% without
cGVHD. The proportion of URD HCT survivors
with hypothyroidism was 6% in those with cGVHD
and 4% in those without. For solid tumors, 3% of
URD HCT survivors with cGVHD versus 1% with-
out cGVHD developed a malignancy.DISCUSSION
To our knowledge, this is the first study of HCT
survivors with acquired SAA to characterize late effects
in the large and representative cohort provided by the
CIBMTR. Compared with previous studies [8-16],
these analyses represent survivors with a wide variety
of ages, from a diverse group of transplantation
centers, who were exposed to a variety of conditioning
regimens and a greater proportion of URD HCT
procedures. We demonstrated that, as a group, HCT
survivors diagnosed with acquired SAA experienced
overall survival of greater than 70%. Despite these
encouraging results, survivors demonstrated a myriad
of late effects, the most common being gonadal
dysfunction in both the MSD and URD groups. For
survivors of MSD HCT, other late effects demo-
nstrated estimated cumulative incidence estimates that
were \3%. Survivors of URD HCT demonstrated
higher cumulative incidence estimates of growth
disturbance, avascular necrosis, hypothyroidism, and
cataracts compared with MSD HCT survivors, with
a notable increase in these estimates over time.
Our analyses confirmed a myriad of late effects
among HCT survivors with acquired SAA including
gonadal dysfunction, growthdisturbance, avascular ne-
crosis, hypothyroidism, cataracts, and malignant neo-
plasms similar to those described in HCT survivors
with malignant disorders [6-16,20-22]. Furthermore,
the prevalence and cumulative incidence of late
effects continues to increase over time. Similar
increases in late effects over time have been described
among survivors of HCT with malignant disorders
[6,7,20-22]. SAA and HCT-related treatment expo-
sures and complications may be associated with sub-
clinical alternations in organ function that become
manifest over time as an HCT survivor ages. The
young median age of the sample and short follow-up
in this report provides one explanation for the low cu-
mulative incidence estimates of many of these late
Biol Blood Marrow Transplant 18:1776-1784, 2012 1783Late Effects after HCT in SAAeffects. Many late effects have a long latency period be-
fore manifestation extending for many years after
HCT. These data suggest the importance of regular
surveillance for late effects among all survivors for an
extended period of time after HCT for acquired SAA.
SAA treatment-related therapy, such as RBC
transfusion-associated iron overload and exposure to
corticosteroids and calcineurin inhibitors, may con-
tribute to the development of endocrinopathies and
avascular necrosis [23-26]. Conditioning-related expo-
sures including busulfan and TBI are also associated
with the development of malignant neoplasms and en-
docrinopathies [27,28]. HCT-related complications
including cGVHD may also contribute to late effects
[29]. Our analyses support these associations as evi-
denced by the finding of a greater burden of late effects
of URD HCT survivors when compared with MSD
HCT recipients. Recipients of URD HCT for ac-
quired SAA experience a greater interval of time
from diagnosis to HCT, which is associated with pro-
longed exposures to immunosuppressive agents, trans-
fusion support, and associated toxicity [23-26]. URD
HCT recipients are also more commonly exposed to
conditioning regimens with TBI and associated
toxicity [27,28]. Furthermore, URD HCT survivors
face greater HCT-related complications including
cGVHD and associated toxicity [29].
Improving survival rates for individuals after HCT
for SAA coupled with data demonstrating the presence
of late effects in these survivors underscores the need
to focus screening efforts on all HCT survivors. Fur-
thermore, characterization of late effects among
HCT survivors with acquired SAA will be critical in
order to ensure optimal survivor health as the applica-
tion of HCT in the treatment of acquired SAA con-
tinues to increase [30].
When interpreting the results of our analyses, there
are several limitations. Data submission with respect to
the outcomes of interest may be inaccurate or incom-
plete despite requirements for reporting, minimal es-
sential data, and on-site audits that suggest the
possibility of under-reporting of late effects. Cumula-
tive incidence estimates may also be underestimated
or differentially reported as long-term survivors with
late effects may no longer be under the care of their
respective transplant center. The wide geographic dis-
tribution of transplant centers may also be associated
with a differential amount of follow-up and reported
late effects among survivors. The follow-up period
was also relatively short, which limited the ability to de-
tect late effects that manifestmany years afterHCT.As
mentioned previously, risk factor analyses using multi-
variable analyses were unsuccessful given the small
number of events in the sample. The retrospective
study design also limited our ability to report on late ef-
fects outside of those queried using the CIBMTR re-
port forms. Outcomes associated with late effectsincluding aspects of quality of life are 1 example of im-
portant data, which are lacking in the CIBMTR data
and other similar registries. Despite these limitations,
this was the largest collection of survivors who under-
went HCT for acquired SAA. The CIBMTR cohort
with more than 450 transplantation centers worldwide
provided a unique opportunity to characterize late ef-
fects in the setting of HCT for acquired SAA. Further-
more, the wide representation of ages, conditioning
exposures, and types of transplant (ie,URDHCT)pro-
vided by the CIBMTR ensured a more accurate depic-
tion of late effects among SAA survivors who
underwent HCT.
In summary, these findings suggest that HCT
survivors with acquired SAA are a robust and healthy
group in general. However, all patients undergoing
HCT are at risk for late effects, must be educated about,
and should bemonitored for late effects. These findings
support the need to develop a clearer understanding of
the burden of and risk factors for late effects after
HCT for acquired SAA. Such an investment would in-
form the further development of evidence-based guide-
lines for the surveillance and amelioration of late effects
[31,32] in order to optimize outcomes among all
survivors of HCT given the ongoing risk for late
morbidity and mortality [33,34].ACKNOWLEDGMENTS
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